文献速递胸部肿瘤消化系统肿瘤乳腺癌

意大利晚期实体瘤患者基因组分析当前实践:可操作突变意大利登记研究(RATIONAL)

Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
PubMed 文献 · Eur J Cancer · 2023-03-30

RATIONAL是一项多中心观察性研究,收集晚期实体瘤患者基于NGS的肿瘤分析数据。研究纳入738例患者(Pathway-A 218例,Pathway-B 520例),Pathway-B使用FoundationOne CDx全面基因组分析。结果显示Pathway-B检出更多II/III级可操作突变和潜在胚系致病变异,573例中67例(11.7%)基于基因组检测接受了靶向治疗。

要点

  • Pathway-B的CGP较Pathway-A标准检测检出更多II/III级可操作突变(99例 vs 20例)和潜在胚系致病变异(58例 vs 15例)。
  • 在非小细胞肺癌、胆管癌、结直肠癌、胃癌、胰腺癌和乳腺癌患者中,254/554例(45.8%)检出ESCAT I/II/III级可操作突变。
  • 原发灶不明肿瘤患者中,CGP检出OncoKB 3B/4级突变的病例为31/58例(53.4%)。

核心结论

  • RATIONAL研究首次概述了意大利当前临床实践中的基因组分析情况,并强调CGP在特定癌症患者中识别治疗靶点的效用。

研究设计与样本

  • 多中心、观察性研究,纳入有可用NGS肿瘤分析(Pathway-A)或在试验内接受FoundationOne CDx全面基因组分析(Pathway-B)的晚期实体瘤患者。
  • 主要终点为可操作突变的识别率;测序数据可及者共738例,其中Pathway-A 218例、Pathway-B 520例。

主要发现

  • Pathway-A中154/218例(70.6%)检测使用≤52基因的NGS panel,164/218例(75.2%)检出基因组改变(GAs);Pathway-B中CGP在512/520例(98.5%)检出GAs。
  • 在非小细胞肺癌、胆管癌、结直肠癌、胃癌、胰腺癌和乳腺癌患者中,254/554例(45.8%)检出ESCAT I/II/III级可操作GAs。
  • Pathway-A与Pathway-B的I级GAs患者数相似(69例 vs 102例)。
  • Pathway-B的CGP较Pathway-A标准检测检出更多II/III级GAs患者(99例 vs 20例)和潜在胚系致病/可能致病变异(58例 vs 15例)。
  • 原发灶不明肿瘤患者中,CGP检出OncoKB 3B/4级GAs者为31/58例(53.4%);总体573例中67例(11.7%)基于基因组检测接受了靶向治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Italian Register of Actionable Mutations (RATIONAL) is a multicentric, observational study collecting next-generation sequencing (NGS)-based tumour profiling data of patients with advanced solid tumours. METHODS: The study enrols patients who had available an NGS-based tumour profiling (Pathway-A) or undergo comprehensive genomic profiling (CGP) with FoundationOne CDx assays within the trial (Pathway-B). The primary endpoint was the rate of actionable mutations identified. RESULTS: Sequencing data were available for 738 patients in Pathway-A (218) and -B (520). In Pathway-A, 154/218 (70.6%) tests were performed using NGS panels ≤52 genes, and genomic alterations (GAs) were found in 164/218 (75.2%) patients. In Pathway-B, CGP revealed GAs in 512/520 (98.5%) patients. Levels I/II/III actionable GAs according to the European Society of Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) were identified in 254/554 (45.8%) patients with non-small-cell lung cancer, cholangiocarcinoma, colorectal, gastric, pancreatic and breast cancer. The rate of patients with level I GAs was similar in Pathways A and B (69 versus 102). CGP in Pathway-B revealed a higher number of patients with level II/III GAs (99 versus 20) and potentially germline pathogenic/likely pathogenic variants (58 versus 15) as compared with standard testing in Pathway-A. In patients with cancer of unknown primary, CGP detected OncoKB levels 3B/4 GAs in 31/58 (53.4%) cases. Overall, 67/573 (11.7%) of patients received targeted therapy based on genomic testing. CONCLUSION: The Italian Register of Actionable Mutations represents the first overview of genomic profiling in Italian current clinical practice and highlights the utility of CGP for identifying therapeutic targets in selected cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Normanno N, De Luca A, Abate RE, et al. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. Eur J Cancer. 2023. PMID: 37167765. doi:10.1016/j.ejca.2023.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。